EUCTR2004-005022-45-HU进行中（未招募）不适用
A Multicenter, Randomized, Double-Blind, Placebo- And Active-Controlled Study of DVS-233 SR for Treatment of Vasomotor Symptoms Associated with Menopause
Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development0 个研究点目标入组 465 人开始时间: 2005年2月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 465
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1.Generally healthy, postmenopausal women of age 40 to 65 seeking treatment for hot flushes with last natural menstrual period (LNMP) completed at least 12 months prior to screening (if LNMP is uncertain, the medical monitor or designee may approve a follicle-stimulating hormone [FSH] level; FSH level > 40 mIU/mL will allow enrollment).
- •2.Intact uterus
- •3.Minimum of 7 moderate to severe hot flushes per day or 50 per week recorded for 7 consecutive days during screening, using the following definitions:·
- •Mild hot flush: sensation of heat without sweating·
- •Moderate hot flush: sensation of heat with sweating, able to continue activity·
- •Severe hot flush: sensation of heat with sweating, causing cessation of activity
- •4.Subjects must have body mass index (BMI) less than or equal to 34 kg/m2 using the nomograph for BMI
- •5.In the opinion of the investigator, the subject will comply with the protocol and has a high probability of completing the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years)
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Known hypersensitivity to venlafaxine (Effexor or Effexor XR) or tibolone
- •2.History, presence or suspicion of estrogen-dependent neoplasia (including endometrial hyperplasia)
- •3.Undiagnosed vaginal bleeding
- •4.Malignancy, or treatment for malignancy, within the previous 2 years, with the exception of basal cell carcinoma of the skin or squamous cell carcinoma of the skin. A history of breast cancer, melanoma, or any gynecologic cancer, at any time, excludes the subject
- •5.Unresolved breast findings (on physical or imaging examinations) suggestive of malignant changes
- •6.Unresolved cervical cytology smear report of atypical glandular cells (AGC). Unresolved atypical squamous cells (ASC). Cervical cytologic smear report of low-grade squamous intraepithelial lesion (LSIL), or greater, cervical intraepithelial neoplasia (CIN) I or greater, or any reported dysplasia
- •7.History of a seizure disorder other than a single childhood febrile seizure
- •8.Active or recent arterial thromboembolic disease (e.g., myocardial infarction or angina)
- •9.History of cerebrovascular accident, stroke, or transient ischemic attack
- •10.History of venous thromboembolism (e.g., deep venous thrombosis, pulmonary embolism)
- •11.History or presence of clinically important hepatic or renal disease or other medical disease that might confound the study or be detrimental to the subject (e.g., clinically important cardiac arrhythmia, clinically important hyponatremia, uncontrolled diabetes, uncontrolled hypertension)
- •12.Endocrine disease (except for controlled hypothyroidism or diet-controlled diabetes mellitus)
- •13.Presence of major depressive disorder, bipolar disorder, psychotic disorder or generalized anxiety disorder requiring therapy
- •14.Gallbladder disease (subjects who have had a cholecystecomy may be enrolled).
- •15.Persistent elevated blood pressure (greater than 160 mm Hg systolic or greater than 100 mm Hg diastolic). Subjects may not be using more than 2 antihypertensive medications for the treatment of hypertension
- •16.Known presence of raised intraocular pressure or history of narrow-angle glaucoma
- •17.Neuro-ocular disorders (e.g., retinal vasculitis)
- •18.Porphyria
- •19.Clinically important abnormalities on screening physical examination, electrocardiogram (ECG) or laboratory tests (e.g., fasting total cholesterol greater than 300 mg/dL, fasting triglycerides greater than 300 mg/dL, fasting blood glucose greater than 125 mg/dL, or serum alanine aminotransferase [ALT] or serum aspartate aminotransferase [AST] greater than 1.5 times the upper limit of normal for the laboratory used)
- •20.Presence of malabsorption disorder
- •21.Use of oral estrogen-, progestin-, androgen- or selective estrogen receptor modulator (SERM)-containing drug products within 8 weeks prior to screening; use of transdermal hormone products within 8 weeks prior to screening; use of vaginal hormone products (rings, creams, gels) within 4 weeks prior to screening; use of intrauterine progestins within 8 weeks prior to screening; use of progestin implants or estrogen injectables within 3 months prior to screening; use of estrogen pellet or progestin injectables within 6 months prior to screening
- •22.Use of any investigational drug within 30 days
- •23.Use of medications thought to relieve VMS within 4 weeks prior to screening, such as aldomet, clonidine, dopaminergic or antidopaminergic drugs (e.g., veralipride), Bellergal (containing belladonna, phenobarbital and ergotamine), gabapentin, he
研究者
相似试验
进行中（未招募）
不适用
A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Dose-Ranging Study with Active-Controlled Long-Term Safety Phase to Assess the Efficacy, Safety and Tolerability of MK-6213 in Patients with Primary Hypercholesterolemia orMixed Hyperlipidemia. - Hypercholesterolemia and hyperlipidemia dose ranging study.Primary hypercholesterolemia or mixed hyperlipidemiaMedDRA version: 9.1Level: LLTClassification code 10020604Term: HypercholesterolemiaEUCTR2007-003684-41-BEMerck Sharp & Dohme BV840
进行中（未招募）
1 期
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433Crohn's Disease (CD)MedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2017-001225-41-ESAbbVie Deutschland GmbH & Co. KG738
进行中（未招募）
1 期
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433Crohn's Disease (CD)MedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2017-001225-41-NLAbbVie Deutschland GmbH & Co. KG738
招募中
3 期
A Multicenter, Randomized, Double-Blind, Placebo- Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433form of Inflammatory Bowel Disease (IBD)10017969Crohn's diseaseNL-OMON54751AbbVie B.V.29
进行中（未招募）
不适用
Comparison of TAK-875 to Placebo and Sitagliptin in Combination with Metformin in Subjects with Type 2 DiabetesType 2 diabetes mellitus (T2DM)MedDRA version: 14.1Level: LLTClassification code 10063624Term: Type II diabetes mellitus inadequate controlSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: LLTClassification code 10029505Term: Non-insulin-dependent diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: LLTClassification code 10012613Term: Diabetes mellitus non-insulin-dependentSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-001752-10-HUTakeda Global Research & Development Centre (Europe) Ltd.1,078